Literature DB >> 23665275

Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.

N Jewel Samadder1, Robert A Vierkant, Lori S Tillmans, Alice H Wang, Daniel J Weisenberger, Peter W Laird, Charles F Lynch, Kristin E Anderson, Amy J French, Robert W Haile, John D Potter, Susan L Slager, Thomas C Smyrk, Stephen N Thibodeau, James R Cerhan, Paul J Limburg.   

Abstract

BACKGROUND & AIMS: Colorectal tumors have a large degree of molecular heterogeneity. Three integrated pathways of carcinogenesis (ie, traditional, alternate, and serrated) have been proposed, based on specific combinations of microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and mutations in BRAF and KRAS. We used resources from the population-based Iowa Women's Health Study (n = 41,836) to associate markers of colorectal tumors, integrated pathways, and clinical and pathology characteristics, including survival times.
METHODS: We assessed archived specimens from 732 incident colorectal tumors and characterized them as microsatellite stable (MSS), MSI high or MSI low, CIMP high or CIMP low, CIMP negative, and positive or negative for BRAF and/or KRAS mutations. Informative marker data were collected from 563 tumors (77%), which were assigned to the following integrated pathways: traditional (MSS, CIMP negative, BRAF mutation negative, and KRAS mutation negative; n = 170), alternate (MSS, CIMP low, BRAF mutation negative, and KRAS mutation positive; n = 58), serrated (any MSI, CIMP high, BRAF mutation positive, and KRAS mutation negative; n = 142), or unassigned (n = 193). Multivariable-adjusted Cox proportional hazards regression models were used to assess the associations of interest.
RESULTS: Patients' mean age (P = .03) and tumors' anatomic subsite (P = .0001) and grade (P = .0001) were significantly associated with integrated pathway assignment. Colorectal cancer (CRC) mortality was not associated with the traditional, alternate, or serrated pathways, but was associated with a subset of pathway-unassigned tumors (MSS or MSI low, CIMP negative, BRAF mutation negative, and KRAS mutation positive) (n = 96 cases; relative risk = 1.76; 95% confidence interval, 1.07-2.89, compared with the traditional pathway).
CONCLUSIONS: We identified clinical and pathology features associated with molecularly defined CRC subtypes. However, additional studies are needed to determine how these features might influence prognosis.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CI; CIMP; CRC; Colon Cancer; CpG island methylator phenotype; IWHS; Integrated Pathways; Iowa Women’s Health Study; MSI; Molecular Epidemiology; PCR; Prognostic Factor; RR; SEER; Surveillance, Epidemiology, and End Results; colorectal cancer; confidence interval; microsatellite instability; polymerase chain reaction; relative risk

Mesh:

Substances:

Year:  2013        PMID: 23665275      PMCID: PMC3772766          DOI: 10.1053/j.gastro.2013.05.001

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  57 in total

1.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

2.  Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.

Authors:  Wade S Samowitz; Hans Albertsen; Carol Sweeney; Jennifer Herrick; Bette J Caan; Kristin E Anderson; Roger K Wolff; Martha L Slattery
Journal:  J Natl Cancer Inst       Date:  2006-12-06       Impact factor: 13.506

3.  Genome-scale analysis of aberrant DNA methylation in colorectal cancer.

Authors:  Toshinori Hinoue; Daniel J Weisenberger; Christopher P E Lange; Hui Shen; Hyang-Min Byun; David Van Den Berg; Simeen Malik; Fei Pan; Houtan Noushmehr; Cornelis M van Dijk; Rob A E M Tollenaar; Peter W Laird
Journal:  Genome Res       Date:  2011-06-09       Impact factor: 9.043

4.  BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

Authors:  Matthew F Kalady; Kathryn L Dejulius; Julian A Sanchez; Awad Jarrar; Xiuli Liu; Elena Manilich; Marek Skacel; James M Church
Journal:  Dis Colon Rectum       Date:  2012-02       Impact factor: 4.585

5.  Patient and tumor characteristics of colon cancers with microsatellite instability: a population-based study.

Authors:  A Chao; F Gilliland; C Willman; N Joste; I M Chen; N Stone; J Ruschulte; D Viswanatha; P Duncan; R Ming; R Hoffman; E Foucar; C Key
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-06       Impact factor: 4.254

6.  Revised TN categorization for colon cancer based on national survival outcomes data.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew K Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.

Authors:  Ludovic Barault; Céline Charon-Barra; Valérie Jooste; Mathilde Funes de la Vega; Laurent Martin; Patrick Roignot; Patrick Rat; Anne-Marie Bouvier; Pierre Laurent-Puig; Jean Faivre; Caroline Chapusot; Francoise Piard
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

8.  Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability.

Authors:  Sanjay Kakar; Guoren Deng; Vaibhav Sahai; Koji Matsuzaki; Hirofumi Tanaka; Soichuro Miura; Young S Kim
Journal:  Arch Pathol Lab Med       Date:  2008-06       Impact factor: 5.534

9.  Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Authors:  Sun Lee; Nam-Yun Cho; Minhee Choi; Eun J Yoo; Jung-Ho Kim; Gyeong H Kang
Journal:  Pathol Int       Date:  2008-02       Impact factor: 2.534

10.  Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Authors: 
Journal:  Genet Med       Date:  2013-02-21       Impact factor: 8.822

View more
  30 in total

1.  Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women.

Authors:  Anna E Prizment; Robert A Vierkant; Thomas C Smyrk; Lori S Tillmans; Heather H Nelson; Charles F Lynch; Thomas Pengo; Stephen N Thibodeau; Timothy R Church; James R Cerhan; Kristin E Anderson; Paul J Limburg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-12-15       Impact factor: 4.254

2.  Long-Term Colorectal Cancer Incidence After Negative Colonoscopy in the State of Utah: The Effect of Family History.

Authors:  N Jewel Samadder; Lisa Pappas; Kenneth M Boucherr; Ken R Smith; Heidi Hanson; Alison Fraser; Yuan Wan; Randall W Burt; Karen Curtin
Journal:  Am J Gastroenterol       Date:  2017-07-11       Impact factor: 10.864

3.  Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.

Authors:  Junli Ma; Yan Zhang; Hong Shen; Linda Kapesa; Wenqiang Liu; Mengsi Zeng; Shan Zeng
Journal:  Tumour Biol       Date:  2015-07-05

4.  Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes.

Authors:  Raaj S Mehta; Mingyang Song; Reiko Nishihara; David A Drew; Kana Wu; Zhi Rong Qian; Teresa T Fung; Tsuyoshi Hamada; Yohei Masugi; Annacarolina da Silva; Yan Shi; Wanwan Li; Mancang Gu; Walter C Willett; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Andrew T Chan
Journal:  Gastroenterology       Date:  2017-02-27       Impact factor: 22.682

5.  Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.

Authors:  Petra Minarikova; Lucie Benesova; Tereza Halkova; Barbora Belsanova; Stepan Suchanek; Jiri Cyrany; Inna Tuckova; Jan Bures; Miroslav Zavoral; Marek Minarik
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

6.  Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort.

Authors:  Rondell P Graham; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Peter W Laird; Daniel J Weisenberger; Charles F Lynch; Amy J French; Susan L Slager; Yassaman Raissian; Joaquin J Garcia; Sarah E Kerr; Hee Eun Lee; Stephen N Thibodeau; James R Cerhan; Paul J Limburg; Thomas C Smyrk
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

Review 7.  Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.

Authors:  Paul Lochhead; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Kana Wu; Reiko Nishihara; Michael O'Brien; Shuji Ogino
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

8.  Distinct patterns of ALDH1A1 expression predict metastasis and poor outcome of colorectal carcinoma.

Authors:  Sen-Lin Xu; Dong-Zu Zeng; Wei-Guo Dong; Yan-Qing Ding; Jun Rao; Jiang-Jie Duan; Qing Liu; Jing Yang; Na Zhan; Ying Liu; Qi-Ping Hu; Xia Zhang; You-Hong Cui; Hsiang-Fu Kung; Shi-Cang Yu; Xiu-Wu Bian
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

9.  Association between molecular subtypes of colorectal cancer and patient survival.

Authors:  Amanda I Phipps; Paul J Limburg; John A Baron; Andrea N Burnett-Hartman; Daniel J Weisenberger; Peter W Laird; Frank A Sinicrope; Christophe Rosty; Daniel D Buchanan; John D Potter; Polly A Newcomb
Journal:  Gastroenterology       Date:  2014-09-30       Impact factor: 22.682

10.  Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

Authors:  Frank A Sinicrope; Qian Shi; Thomas C Smyrk; Stephen N Thibodeau; Rodrigo Dienstmann; Justin Guinney; Brian M Bot; Sabine Tejpar; Mauro Delorenzi; Richard M Goldberg; Michelle Mahoney; Daniel J Sargent; Steven R Alberts
Journal:  Gastroenterology       Date:  2014-10-08       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.